By exposing the disease-relevant mechanisms involved, this work reveals that BTK inhibition is a therapeutic approach that meets the need for selectively targeting pathogenic B cells in MS and other types inflammatory and autoimmune disorders (17, 21, 49). Here, BTK is linked to autoimmune disease.